| 摘要 |
The present application relates to compounds having the inhibitory activity to apoptosis signal-regulating kinase (ASK1), thus are thus useful in treating ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, COPD, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases. |
| 主权项 |
1. A compound of Formula (I):wherein:
R1 is C1-C6 alkyl, C3-C6 cycloalkyl, or C2-C6 heterocycloalkyl, wherein the alkyl, cycloalkyl, or heterocycloalkyl moiety is optionally substituted with one to four members independently selected from halo, OR11, and NR11R12; R2 is hydrogen or C1-C3 alkyl; R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is C1-C6 alkyl, C3-C6 cycloalkyl, or C2-C6 heterocycloalkyl, wherein the alkyl, cycloalkyl, or heterocycloalkyl moiety is optionally substituted with one to four members independently selected from halo, OR11, and NR11R12; R7 is hydrogen or C1-C3 alkyl; and Ra and Rb combine with the nitrogen atom to which they are attached to form a four to ten member heterocyclic group that is a monocyclic group or a fused or bridged bicyclic, or spirocyclic group optionally containing an oxygen or a nitrogen atom in the heterocyclic group, wherein the heterocyclic group is further optionally substituted with one to four members, at the same atom or different atom, independently selected from C1-C6 alkyl, hydroxyl, cyano, oxo, halo, C1-C6 carbonyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C2-C6 heterocycloalkyl, C1-C6 acyl, C1-C6 alkyl-R11, OR11, C(O)NR11; wherein R11 and R12 is independently selected from hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl;or a pharmaceutically acceptable salt or stereoisomer thereof. |
